Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Ann Surg. 2014 Dec;260(6):1112–1120. doi: 10.1097/SLA.0000000000000631

Figure 7.

Figure 7

Administration of the intestinal specific mast cell degranulation inhibitor doxantrazole decreased gut permeability (7A) following T/HS, but did not alter the extent of mucus loss (7B). Data are expressed as mean ± SEM with 5–6 animals per group. *p<0.05 vs. T/HS + vehicle.